NCT00805675View on ClinicalTrials.gov

Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB

PHASE3CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

December 31, 2010

Conditions
Hepatitis B Virus
Interventions
DRUG

Telbivudine

600 mg monotherapy supplied in film-coated tablets.

DRUG

Tenofovir

Tenofovir disoproxil fumarate was supplied in 300 mg tablets

DRUG

Telbivudine plus tenofovir

Telbivudine 600 mg and Tenofovir 300 mg were purchased in commercial packs. Patients were instructed to take medication(s) orally every morning either with or without food.

Trial Locations (1)

Unknown

Department of Medicine, Queen Mary Hospital, Hong Kong

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY